Dani Monroe was named chief diversity and inclusion officer at Partners Healthcare.
Pfizer's fourth-quarter profit fell by half due to higher costs for production, administration and restructuring, but new revenue from an acquisition helped the world's second-biggest drugmaker beat Wall Street expectations.
Last year ended as frenzied as it began for healthcare dealmakers. Globally, merger and acquisition activity reached record volume in 2015, and the value of global healthcare deals increased 66% last year to $723.7 billion, according to Dealogic.
More than 80 pharmaceutical, diagnostic and biotech firms are calling for increased government investment of new antibiotic drugs to address the growing threat posed by drug-resistant infections coupled with dwindling innovation of new treatments.
Healthcare entered 2016 with market turmoil, and not because of China's economy. Investors grew anxious after third-quarter results last year suggested that the Affordable Care Act's boost to hospitals—and related companies such as staffing firms—had begun to wane.
Approvals for first-of-a-kind drugs climbed last year, pushing the annual tally of new U.S. drugs to its highest level in 19 years. The figures reflect a focus on drugs for rare and hard-to-treat diseases, which often come with streamlined reviews, extra patent protections and higher price tags.
Last year ushered in a bevy of new rules and regulations that are already affecting the healthcare industry. But 2016 is expected to be just as eventful.
Albert Bourla, group president of vaccines, oncology and consumer healthcare businesses at Pfizer, spoke with Modern Healthcare about his company's research and development strategies, how Pfizer is responding to consumer-directed healthcare and the controversy over high drug prices.
Albert Bourla, group president of vaccines, oncology and consumer healthcare businesses at Pfizer, discusses his company's research and development strategies, how Pfizer is responding to consumer-directed healthcare and the controversy over high drug prices. He spoke with Modern Healthcare...
Pfizer's $160 billion deal to acquire Irish drugmaker Allergan got a lot of attention for the tax advantages Pfizer would enjoy from moving its New Jersey headquarters overseas to Dublin. There wasn't much talk, though, about how much the deal would expand Pfizer's footprint in biosimilars.
The boards of Pfizer and Ireland's Allergan on Sunday approved a merger deal worth $160 billion. The deal would create the largest drugmaker by sales.
An expected deal between pharmaceutical giants Pfizer and Allergan that's expected to be worth up to $380 a share could become less lucrative under new U.S. Treasury rules designed to diminish the benefits of cross-border transactions.